Cell Genesys President Elected to California Healthcare Institute Board.Business Editors/Health/Medical Writers BIOWIRE2K LA JOLLA La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and , Calif.--(BUSINESS WIRE)--April 22, 2003 Joseph J. Vallner, Ph.D., president and chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , Cell Genesys, a biotechnology company focused on developing and commercializing novel biological therapies for patients with cancer, was elected to the board of directors of California Healthcare Institute (CHI) in April. CHI is a non-profit public policy research organization representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms. "Cell Genesys with its diverse, oncology-focused product portfolio and extensive technology and patent estate, is a shining example of California's global leadership in biotechnology," said David Gollaher, Ph.D., president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , CHI. "We are fortunate to have Joe's exceptional wealth of talent and practical experience on our board of directors." Vallner joined Cell Genesys in October 1999. Prior to Cell Genesys, he was with SEQUUS Pharmaceuticals for seven years where he was instrumental in the launch of two products including Doxil(R), a liposome-based cancer therapeutic. He also helped transition the company through its merger with ALZA Corp. Prior to SEQUUS, he held various positions with Syntex Corp. and G.D. Searle and Co., and was an associate professor of pharmaceutics at the University of Georgia Organization The President of the University of Georgia (as of 2007, Michael F. Adams) is the head administrator and is appointed and overseen by the Georgia Board of Regents. prior to that. He received his Ph.D. in pharmaceutics, an M.S. in physical chemistry and a B.S. in pharmacy from the University of Wisconsin, Madison. Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is pursuing three cancer product platforms -- GVAX(R) cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine , oncolytic virus An oncolytic virus is a virus used to treat cancer due to their ability to specifically infect cancer cells, while leaving normal cells unharmed. Viruses can be engineered to be replication competent only in cancer cells, leading to cell lysis and dose amplification at the site of therapies and cancer gene therapies. Cell Genesys has headquarters in South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. and has manufacturing operations in San Diego, Hayward, Calif. and Memphis, Tenn. The company's Web site is www.cellgenesys.com. CHI represents more than 200 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI's mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI's Web site is www.chi.org. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion